10 results about "Gpr119 agonist" patented technology

This disclosure relates to an oral pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt thereof. In formula JPEG2026528933000058.jpg30170, R, A, and n are as described herein. This disclosure also relates to the preparation processes thereof, as well as their use in the treatment of disorders such as cardiovascular and metabolic disorders, including diabetes.

The present invention relates to the use of GPR119 agonists for the treatment and / or prevention of weight related diseases and disorders such as obesity and corpulence.

This invention relates to the solid form of the GPR119 agonist of formula I and a process for preparing the same. In particular, this invention relates to the crystalline form of the compound of formula I and the preparation thereof. JPEG2026528934000006.jpg31170

The present invention relates to solid forms of GPR119 agonists of formula I and processes for their preparation. In particular, the present invention relates to crystalline forms of compounds of formula I and their preparation.

This disclosure relates to the use of GPR119 agonists for the treatment and / or prevention of metabolic-related diseases and disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

The invention provides sulindac as a GPR119 agonist and application of sulindac in preparation of a product for improving IFPD, and belongs to the technical field of new application of drugs. The invention particularly provides application of sulindac as a non-steroidal anti-inflammatory drug in preparation of a GPR119 agonist product and application of sulindac in preparation of a product for improving fat deposition in pancreas. A sulindac intervention experiment shows that the expression of the sulindac on GPR119 / CaM / AKT / Foxo1 pathway protein of a C57BL / 6J mouse tends to a normal level, which indicates that the sulindac has the potential as a GPR119 agonist and also has the effect of improving IPFD.

The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto.

This disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, as well as improved processes for the preparation and purification of intermediates thereof. JPEG2026528935000077.jpg25170